PT1410791E - Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção - Google Patents

Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção Download PDF

Info

Publication number: PT1410791E
Authority: PT; Portugal
Prior art keywords: oralentally; metformina; comprehending; administered; galenic form
Prior art date: 1998-02-23

Application number

PT04001294T

Other languages

English (en)

Inventor

Philippe Giet

Olivier Saslawski

Dominique Revol

Thierry Hulot

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-23

Filing date

1999-02-16

Publication date

2008-12-24

1999-02-16 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2008-12-24 Publication of PT1410791E publication Critical patent/PT1410791E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Addiction (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT04001294T 1998-02-23 1999-02-16 Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção PT1410791E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9802143A FR2775188B1 (fr)	1998-02-23	1998-02-23	Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption

Publications (1)

Publication Number	Publication Date
PT1410791E true PT1410791E (pt)	2008-12-24

Family

ID=9523244

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT04001294T PT1410791E (pt)	1998-02-23	1999-02-16	Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção
PT99913165T PT1056445E (pt)	1998-02-23	1999-02-16	Orcao forma galenica de libertacao imediata e de libertacao prolongada administravel oralmente compreendendo um agente promotor da absorcao e utilizacao deste agentepromotor da abs

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT99913165T PT1056445E (pt)	1998-02-23	1999-02-16	Orcao forma galenica de libertacao imediata e de libertacao prolongada administravel oralmente compreendendo um agente promotor da absorcao e utilizacao deste agentepromotor da abs

Country Status (27)

Country	Link
US (2)	US6426087B1 (pt)
EP (2)	EP1056445B1 (pt)
JP (1)	JP4828020B2 (pt)
KR (1)	KR100587181B1 (pt)
CN (1)	CN1182837C (pt)
AP (1)	AP2000001943A0 (pt)
AR (2)	AR018109A1 (pt)
AT (2)	ATE408399T1 (pt)
AU (1)	AU750785B2 (pt)
BR (1)	BR9908121A (pt)
CA (1)	CA2321267C (pt)
CZ (1)	CZ299366B6 (pt)
DE (2)	DE69917750T2 (pt)
DK (2)	DK1410791T3 (pt)
ES (2)	ES2314302T3 (pt)
FR (1)	FR2775188B1 (pt)
HU (1)	HU226732B1 (pt)
ID (1)	ID26022A (pt)
NO (1)	NO20004190L (pt)
OA (1)	OA11454A (pt)
PL (2)	PL191415B1 (pt)
PT (2)	PT1410791E (pt)
RU (1)	RU2228201C2 (pt)
SI (2)	SI1410791T1 (pt)
SK (2)	SK285188B6 (pt)
WO (1)	WO1999042086A1 (pt)
ZA (1)	ZA991408B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9925127D0 (en) *	1999-10-22	1999-12-22	Pharmacia & Upjohn Spa	Oral formulations for anti-tumor compounds
FR2805462B1 (fr) *	2000-02-24	2003-08-15	Therabel Res	Nouvelle forme galenique orale a liberation prolongee de la molsidomine
DE10026699A1 (de)	2000-05-30	2001-12-06	Basf Ag	Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US7183410B2 (en) *	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US20030060475A1 (en) *	2001-08-10	2003-03-27	Boehringer Ingelheim Pharma Kg	Method of using flibanserin for neuroprotection
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
SE0200475D0 (sv) *	2002-02-15	2002-02-15	Ltp Lipid Technologies Provide	Oral farmaceutisk beredning
EP1499306A4 (en)	2002-04-12	2007-03-28	Merck & Co Inc	BICYCLIC AMIDE
US20040048877A1 (en) *	2002-05-22	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions containing flibanserin
US10004729B2 (en)	2002-07-05	2018-06-26	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
FR2845289B1 (fr) *	2002-10-04	2004-12-03	Ethypharm Sa	Spheroides, procede de preparation et compositions pharmaceutiques.
CA2823937A1 (en) *	2002-10-07	2004-04-22	Novartis Vaccines And Diagnostics, Inc.	Hiv vaccine formulations
US20040151769A1 (en) *	2002-12-31	2004-08-05	Boehringer Ingelheim International Gmbh	Film coated tablet containing an extract of red vine leaves
ITRM20030074A1 (it) *	2003-02-21	2004-08-22	Pharmacia Italia Spa	Formulazioni semisolide a rilascio immediato intese
US20040241252A1 (en) *	2003-05-29	2004-12-02	Abney Christopher Charles	Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
RU2241449C1 (ru) *	2003-09-25	2004-12-10	Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин"	Фармацевтическая композиция для лечения диабета (варианты)
WO2005060942A1 (en) *	2003-12-19	2005-07-07	Aurobindo Pharma Ltd	Extended release pharmaceutical composition of metformin
US20050239798A1 (en) *	2004-04-22	2005-10-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Method for the treatment of premenstrual and other female sexual disorders
BRPI0510074A (pt) *	2004-04-22	2007-10-16	Boehringer Ingelheim Int	composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20080181946A1 (en) *	2004-05-14	2008-07-31	Braj Bhushan Lohray	Controlled Release Delivery System For Metformin
CA2569958C (en)	2004-06-12	2016-03-22	Jane C. Hirsh	Abuse-deterrent drug formulations
US20060024370A1 (en) *	2004-07-29	2006-02-02	Cephalon France	Modafinil oral lyophilizate
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (en) *	2004-09-03	2007-05-30	Boehringer Ingelheim International GmbH	Method for the treatment of attention deficit hyperactivity disorder
PL1796621T5 (pl) *	2004-10-01	2014-09-30	Firmenich & Cie	Mikrokapsułki perfumujące lub aromatyzujące zawierające element tłumiący wybuch
WO2006096439A2 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599937A1 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20060211685A1 (en) *	2005-03-04	2006-09-21	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of depression
PE20061245A1 (es) *	2005-03-30	2007-01-06	Generex Pharm Inc	Composiciones para la transmision transmucosa oral de la metformina
WO2006119884A2 (en) *	2005-05-06	2006-11-16	Boehringer Ingelheim International Gmbh	Method for the treatment of drug abuse with flibanserin
WO2006125041A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) *	2005-05-19	2006-11-23	Boehringer Ingelheim International Gmbh	Method for the treatment of drug-induced sexual dysfunction
BRPI0612752B8 (pt) *	2005-06-21	2021-05-25	Merck Patent Gmbh	composição farmacêutica sólida compreendendo (r)-(-)-2-[5-(4-fluorfenil)-3-piridilmetilaminometil]cromano
EP1745788A1 (de) *	2005-07-22	2007-01-24	KTB Tumorforschungsgesellschaft mbH	Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
PL1912650T3 (pl)	2005-08-03	2018-01-31	Sprout Pharmaceuticals Inc	Zastosowanie flibanseryny w leczeniu otyłości
US20070123540A1 (en) *	2005-10-29	2007-05-31	Angelo Ceci	Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) *	2005-10-29	2013-12-24	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) *	2005-11-08	2007-05-10	Stephane Pollentier	Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007106957A1 (en) *	2006-03-21	2007-09-27	Laboratoires Smb S.A.	Multiple units controlled-release floating dosage forms
EA200802208A1 (ru) *	2006-05-09	2009-04-28	Бёрингер Ингельхайм Интернациональ Гмбх	Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
EP2037927B1 (en) *	2006-06-30	2010-01-27	Boehringer Ingelheim International GmbH	Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) *	2006-07-14	2009-04-08	Boehringer Ingelheim International GmbH	Use of flibanserin for the treatment of sexual disorders in females
AR062320A1 (es) *	2006-08-14	2008-10-29	Boehringer Ingelheim Int	Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) *	2006-08-14	2008-03-07	Boehringer Ingelheim Int	Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) *	2006-08-25	2008-02-28	Boehringer Ingelheim International Gmbh	Controlled release system and method for manufacturing the same
US20080081142A1 (en) *	2006-10-03	2008-04-03	Zeik Douglas B	Articles and methods for applying color on surfaces
EP1952803A1 (en)	2007-01-23	2008-08-06	KTB-Tumorforschungs GmbH	Solid pharmaceutical dosage form containing hydrogenated phospholipids
US20090082464A1 (en) *	2007-09-07	2009-03-26	Bernd Jandeleit	Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US8168617B2 (en) *	2007-09-07	2012-05-01	Xenoport, Inc.	Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
CL2008002693A1 (es) *	2007-09-12	2009-10-16	Boehringer Ingelheim Int	Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2042165A1 (de) *	2007-09-28	2009-04-01	Swiss Caps Rechte und Lizenzen AG	Hot-Melt-Befüllte Weichkapseln
US20090099253A1 (en) *	2007-10-15	2009-04-16	Xenoport, Inc.	Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
CA2638240C (en) *	2008-08-29	2010-02-02	Alexander Macgregor	Method of treating dysglycemia and glucose excursions
US8226967B2 (en)	2008-11-27	2012-07-24	Basf Se	Surface active proteins as excipients in solid pharmaceutical formulations
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP5714600B2 (ja)	2009-12-18	2015-05-07	フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａＮｅｄｅｒｌａｎｄＨｏｌｄｉｎｇＢ．Ｖ．	共加工された錠用賦形剤混合物、その調製及び使用
JP5546900B2 (ja) *	2010-02-25	2014-07-09	ライオン株式会社	パナキサトリオール安定化組成物
CA2850468C (en)	2010-09-28	2019-08-13	Depomed, Inc.	Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
SG11201403785UA (en) *	2011-12-02	2014-10-30	Synchroneuron Inc	Acamprosate formulations, methods of using the same, and combinations comprising the same
US20130143867A1 (en) *	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20160023641A (ko) *	2013-03-15	2016-03-03	아이슈티카 인코포레이티드	아비라테론 아세테이트 제제
US20150246060A1 (en)	2013-03-15	2015-09-03	Iceutica Inc.	Abiraterone Acetate Formulation and Methods of Use
CN105431144A (zh)	2013-06-05	2016-03-23	思康脑侒股份有限公司	阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US20150157646A1 (en)	2013-09-27	2015-06-11	Iceutica Inc.	Abiraterone Steroid Formulation
WO2017222575A1 (en)	2016-06-23	2017-12-28	Collegium Pharmaceutical, Inc.	Process of making more stable abuse-deterrent oral formulations
IL270654B2 (en)	2017-05-17	2024-07-01	Confluence Pharmaceuticals Llc	Formulations of homotaurines and salts thereof
JP2024530727A (ja)	2021-08-25	2024-08-23	ビーエーエスエフソシエタス・ヨーロピア	直接打錠補助組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI63335B (fi) *	1979-02-02	1983-02-28	Orion Yhtymae Oy	Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
FR2457281A1 (fr) *	1979-05-23	1980-12-19	Meram Lab	Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
GB8524421D0 (en) *	1985-10-03	1985-11-06	Boots Co Plc	Therapeutic agents
JPS62265226A (ja) *	1986-05-12	1987-11-18	Fujisawa Pharmaceut Co Ltd	経口投与用製剤
US5190748A (en) *	1988-11-22	1993-03-02	Hoffmann-La Roche Inc.	Absorption enhancement of antibiotics
ZA898331B (en) *	1988-11-22	1990-07-25	Hoffmann La Roche	Pharmaceutical compositions
US5139786A (en) *	1989-07-07	1992-08-18	Ciba-Geigy Corporation	Topical formulations
JPH03275633A (ja) *	1990-03-23	1991-12-06	Teikoku Seiyaku Co Ltd	生理活性ポリペプチドの吸収促進剤
US5138786A (en)	1991-07-17	1992-08-18	Fischer Michael G	Insta-guard firearm protection
IT1255895B (it) *	1992-10-20	1995-11-17	Laura Chiodini	Composizioni farmaceutiche contenenti una calcitonina
DE4432757A1 (de) *	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US5858398A (en) *	1994-11-03	1999-01-12	Isomed Inc.	Microparticular pharmaceutical compositions
JP3275633B2 (ja)	1995-06-16	2002-04-15	松下電器産業株式会社	脱水兼用洗濯機
GB9516268D0 (en) *	1995-08-08	1995-10-11	Danbiosyst Uk	Compositiion for enhanced uptake of polar drugs from the colon

1998
- 1998-02-23 FR FR9802143A patent/FR2775188B1/fr not_active Expired - Fee Related
1999
- 1999-02-16 JP JP2000532103A patent/JP4828020B2/ja not_active Expired - Fee Related
- 1999-02-16 SI SI9931019T patent/SI1410791T1/sl unknown
- 1999-02-16 ES ES04001294T patent/ES2314302T3/es not_active Expired - Lifetime
- 1999-02-16 SI SI9930637T patent/SI1056445T1/xx unknown
- 1999-02-16 CA CA002321267A patent/CA2321267C/en not_active Expired - Fee Related
- 1999-02-16 CN CNB998032182A patent/CN1182837C/zh not_active Expired - Fee Related
- 1999-02-16 DK DK04001294T patent/DK1410791T3/da active
- 1999-02-16 DK DK99913165T patent/DK1056445T3/da active
- 1999-02-16 DE DE69917750T patent/DE69917750T2/de not_active Expired - Lifetime
- 1999-02-16 PL PL342162A patent/PL191415B1/pl unknown
- 1999-02-16 AT AT04001294T patent/ATE408399T1/de active
- 1999-02-16 ID IDW20001870A patent/ID26022A/id unknown
- 1999-02-16 PL PL377398A patent/PL201851B1/pl unknown
- 1999-02-16 EP EP99913165A patent/EP1056445B1/en not_active Expired - Lifetime
- 1999-02-16 DE DE69939605T patent/DE69939605D1/de not_active Expired - Lifetime
- 1999-02-16 CZ CZ20002940A patent/CZ299366B6/cs not_active IP Right Cessation
- 1999-02-16 RU RU2000124535/15A patent/RU2228201C2/ru not_active IP Right Cessation
- 1999-02-16 AP APAP/P/2000/001943A patent/AP2000001943A0/en unknown
- 1999-02-16 AU AU31408/99A patent/AU750785B2/en not_active Ceased
- 1999-02-16 US US09/622,663 patent/US6426087B1/en not_active Expired - Lifetime
- 1999-02-16 PT PT04001294T patent/PT1410791E/pt unknown
- 1999-02-16 SK SK1255-2000A patent/SK285188B6/sk not_active IP Right Cessation
- 1999-02-16 SK SK5107-2005A patent/SK286248B6/sk not_active IP Right Cessation
- 1999-02-16 WO PCT/EP1999/000994 patent/WO1999042086A1/en not_active Ceased
- 1999-02-16 BR BR9908121-0A patent/BR9908121A/pt not_active Application Discontinuation
- 1999-02-16 AT AT99913165T patent/ATE268164T1/de active
- 1999-02-16 EP EP04001294A patent/EP1410791B1/en not_active Expired - Lifetime
- 1999-02-16 ES ES99913165T patent/ES2222695T3/es not_active Expired - Lifetime
- 1999-02-16 HU HU0100970A patent/HU226732B1/hu not_active IP Right Cessation
- 1999-02-16 PT PT99913165T patent/PT1056445E/pt unknown
- 1999-02-16 KR KR1020007009307A patent/KR100587181B1/ko not_active Expired - Fee Related
- 1999-02-22 ZA ZA9901408A patent/ZA991408B/xx unknown
- 1999-02-23 AR ARP990100731A patent/AR018109A1/es active IP Right Grant
2000
- 2000-08-22 NO NO20004190A patent/NO20004190L/no not_active Application Discontinuation
- 2000-08-22 OA OA1200000231A patent/OA11454A/en unknown
2002
- 2002-03-19 US US10/100,084 patent/US6514524B1/en not_active Expired - Lifetime
2008
- 2008-06-04 AR ARP080102354A patent/AR066843A2/es active IP Right Grant

Also Published As

Publication number	Publication date
WO1999042086A9 (en)	2000-08-31
FR2775188A1 (fr)	1999-08-27
NO20004190D0 (no)	2000-08-22
SI1056445T1 (en)	2004-10-31
BR9908121A (pt)	2000-10-24
EP1410791B1 (en)	2008-09-17
CA2321267C (en)	2007-04-17
SK285188B6 (sk)	2006-08-03
OA11454A (en)	2003-12-08
ES2222695T3 (es)	2005-02-01
HU226732B1 (en)	2009-08-28
DK1410791T3 (da)	2009-01-12
HUP0100970A3 (en)	2001-12-28
HK1035142A1 (en)	2001-11-16
KR20010034537A (ko)	2001-04-25
US6514524B1 (en)	2003-02-04
DK1056445T3 (da)	2004-10-04
HUP0100970A2 (hu)	2001-08-28
US6426087B1 (en)	2002-07-30
DE69939605D1 (de)	2008-10-30
DE69917750T2 (de)	2005-05-25
PL191415B1 (pl)	2006-05-31
PL342162A1 (en)	2001-05-21
AR018109A1 (es)	2001-10-31
PT1056445E (pt)	2004-10-29
AU750785B2 (en)	2002-07-25
WO1999042086A1 (en)	1999-08-26
EP1410791A1 (en)	2004-04-21
ZA991408B (en)	1999-08-23
RU2228201C2 (ru)	2004-05-10
SK12552000A3 (sk)	2001-02-12
SI1410791T1 (sl)	2009-02-28
FR2775188B1 (fr)	2001-03-09
PL201851B1 (pl)	2009-05-29
ATE408399T1 (de)	2008-10-15
CZ299366B6 (cs)	2008-07-02
KR100587181B1 (ko)	2006-06-08
ES2314302T3 (es)	2009-03-16
NO20004190L (no)	2000-10-20
AU3140899A (en)	1999-09-06
JP2002503686A (ja)	2002-02-05
ID26022A (id)	2000-11-16
ATE268164T1 (de)	2004-06-15
EP1056445B1 (en)	2004-06-02
JP4828020B2 (ja)	2011-11-30
EP1056445A1 (en)	2000-12-06
CA2321267A1 (en)	1999-08-26
CZ20002940A3 (cs)	2000-11-15
CN1291091A (zh)	2001-04-11
AR066843A2 (es)	2009-09-16
CN1182837C (zh)	2005-01-05
SK286248B6 (sk)	2008-06-06
DE69917750D1 (de)	2004-07-08
AP2000001943A0 (en)	2000-12-31

Publication	Publication Date	Title
PT1410791E (pt)	2008-12-24	Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção
LV10082A (lv)	1994-05-10	Propenskabes atvasinajumi to iegusanas panemiens sastavs un pielietosana senisu kukainu un ercu apkarosanai
LV12624B (lv)	2001-09-20	Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
FI912858A7 (fi)	1991-06-13	Haavojen parantamisessa aktiivisia polypeptidipolymeerikonjugaatteja
CY1107649T1 (el)	2013-04-18	Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
PT1009400E (pt)	2005-02-28	Terapeutica combinada compreendendo atorvastatina e um agente anti-hipertensor
DE69806831D1 (de)	2002-09-05	Dithiolan Derivate, deren Herstellung und deren Heileffekt
ID22565A (id)	1999-11-11	Penggunaan nanodispersi dalam formulasi akhir obat
CY2013001I1 (el)	2015-10-07	Nεα παραγωγα κινουκλιδινης και ιατρικα σκευασματα που τα πepιεχουν
EE200300103A (et)	2005-02-15	Kontratseptsioonimeetod ja kontratseptiivi manustatav vorm
DE60034476D1 (de)	2007-05-31	Topische nasenbehandlung mit desloratadin und mometason furoat
ATE280583T1 (de)	2004-11-15	Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
LV10953A (lv)	1995-12-20	Aizvietotie benzimidazoli to iegusanas panemiens pielietojums farmaceitiska kompozicija
FI971188L (fi)	1997-05-20	Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
EE200100559A (et)	2003-02-17	Atsetüülsalitsüülhapet ja klopidogreelvesiniksulfaati sisaldav farmatseutiline kompositsioon üksikannusvormis
ID28441A (id)	2001-05-24	Terapi untuk memperbaiki kesadaran
CO5160321A1 (es)	2002-05-30	Novedosas composiciones de tipranavir y ritonavir
MX9301136A (es)	1993-12-01	Composiciones que contienen psyllium.
EE200300371A (et)	2003-10-15	Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
NO20016068D0 (no)	2001-12-12	Anvendelse av oksypurin-nukleosider for fremstilling av et farmasöytisk preparat for redusering av inflammasjon i et dyr
FI964936L (fi)	1997-02-06	Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
ID29494A (id)	2001-08-30	Pengatasan dalam atau kaitannya terhadap pengurangan bau
ITMI991625A0 (it)	1999-07-23	Formulazioni ottimizzate costituite da soluzioni di steroidi da sommin istrare per inalazione
PT1058544E (pt)	2005-04-29	Inibicao da actividade do tnf
ID24062A (id)	2000-07-06	Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing